Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - Æxlishemjandi lyf - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

aspen pharma trading limited - azathioprinum inn - filmuhúðuð tafla - 25 mg

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

aspen pharma trading limited - azathioprinum inn - filmuhúðuð tafla - 50 mg

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

accord healthcare b.v. - mycophenolatum natríum - magasýruþolin tafla - 180 mg

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

accord healthcare b.v. - mycophenolatum natríum - magasýruþolin tafla - 360 mg

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 180 mg

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 360 mg

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - mycophenolatum mofetil - filmuhúðuð tafla - 500 mg

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

astellas pharma a/s* - tacrolimusum mónohýdrat - hart hylki - 0,5 mg

Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

astellas pharma a/s* - tacrolimusum mónohýdrat - hart hylki - 1 mg